洛美沙星在泌尿生殖系统感染治疗与预防中的应用

[Lomefloxacin in the treatment and prevention of urogenital infection].

作者信息

Perepanova T S, Darenkov A F, Kotliarova G A, Kondrat'eva E M, Siniukhin V N, Beshliev D A

出版信息

Urol Nefrol (Mosk). 1995 May-Jun(3):31-2.

Abstract

A new antibiotic from fluoroquinolone series maxaquine (lomefloxacin) made in USA (Searle [correction of Surl]) has been tried in the treatment of urogenital infection (chronic cystitis, prostatitis, pyelonephritis, acute epididymitis, chlamydial urethroprostatitis) as well as to warrant antibacterial preparation before extracorporeal lithotripsy. The duration of the treatment course (3-28 days) was oriented to nosological form. The 24-h dose ranged from 400 to 800 mg. Side effects manifested with dyspepsia in 4 patients, worsening of memory in 2 patients. Photosensitization did not occur. Maxaquine clinical efficacy is similar to aminoglycosides and is superior to cephalosporins of the third generation. As for fluoroquinolone antibiotics, maxaquine can be compared to cyprofloxacine. The drug proved effective against urethroprostatitis and urethrocystitis of chlamydial origin. The responses to maxaquine favour its application in hospitals as second-line drug, whereas outpatiently it can be used for short-term empiric therapy.

摘要

一种来自美国（先灵葆雅公司 [原文“Surl”有误，应为“Searle”]）生产的氟喹诺酮类新型抗生素麦拉克辛（洛美沙星）已被用于治疗泌尿生殖系统感染（慢性膀胱炎、前列腺炎、肾盂肾炎、急性附睾炎、衣原体性尿道前列腺炎），以及作为体外冲击波碎石术前的抗菌准备用药。治疗疗程（3 - 28天）根据疾病类型而定。24小时剂量范围为400至800毫克。4例患者出现消化不良、2例患者记忆力减退等副作用。未发生光敏反应。麦拉克辛的临床疗效与氨基糖苷类相似，优于第三代头孢菌素。至于氟喹诺酮类抗生素，麦拉克辛可与环丙沙星相媲美。该药物被证明对衣原体性尿道前列腺炎和尿道膀胱炎有效。麦拉克辛的疗效支持其在医院作为二线药物使用，而在门诊可用于短期经验性治疗。